Lonza Group AG
LONN
Rang in Aktien
#449
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aktienkurs
$763.31
Marktkapitalisierung
$53.31B
Veränderung (1 Tag)
0.87%
Veränderung (1 Jahr)
8.49%
Land
CH
Handel Lonza Group AG (LONN)
Kategorie
Healthcare
Gewinn für Lonza Group AG (LONN)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Lonza Group AG betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Lonza Group AG von 2004 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2025 | $1.39B | 77.01% |
| 2024 | $783.78M | -16.56% |
| 2023 | $939.36M | -40.02% |
| 2022 | $1.57B | 87.88% |
| 2021 | $833.60M | -4.61% |
| 2020 | $873.87M | 18.24% |
| 2019 | $739.09M | -9.57% |
| 2018 | $817.28M | 49.73% |
| 2017 | $545.84M | 48.94% |
| 2016 | $366.48M | 7.42% |
| 2015 | $341.15M | 21.46% |
| 2014 | $280.87M | 138.68% |
| 2013 | $117.67M | -48.71% |
| 2012 | $229.45M | 23.16% |
| 2011 | $186.30M | -47.24% |
| 2010 | $353.12M | 96.17% |
| 2009 | $180.00M | -59.52% |
| 2008 | $444.71M | 39.23% |
| 2007 | $319.41M | 55.15% |
| 2006 | $205.88M | 36.16% |
| 2005 | $151.21M | -3.96% |
| 2004 | $157.45M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
